Anna French Ph.D. is an associate at Qiming Ventures Partners, based in Boston. Prior to joining Qiming Ventures in July 2017, Dr. French was a management consultant at the Boston Consulting Group (BCG) where she advised top 10 global biopharma companies on their strategy and operations across a range of topic areas including portfolio strategy, clinical operations, digital in R&D, regulatory, NewCo launch, PMO and due diligence. Prior to BCG, Dr. French led an global industry-academic consortium focused on cell therapy commercialization.
Dr. French earned a Ph.D. (D.Phil) from the University of Oxford, UK in Clinical Laboratory Sciences where her research focused on hematological applications of human induced pluripotent stem (iPS) cells. She has a 1st Class BSc. in Biochemistry from the University of Bristol, UK
Dr. French has over 20 publications in the field of stem cell research, including in Cell Stem Cell, Nature Biotechnology and Trends in Biotechnology. She is an editorial board member for 'Current Stem Cell Research & Therapy’ and an invited reviewer for a number of journals.